{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:10:19Z","timestamp":1794557419887,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Royal Dutch Pharmacists Association"},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41431-025-02008-3","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:37:02Z","timestamp":1768250222000},"page":"379-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction between CYP2D6 and CYP2C19 and tricyclic antidepressants"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5008-244X","authenticated-orcid":false,"given":"Kristian","family":"Kleine Schaars","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-6867","authenticated-orcid":false,"given":"Marga","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Soree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke J.","family":"de Boer-Veger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-7266","authenticated-orcid":false,"given":"Elisa J. F.","family":"Houwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Risselada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A. P. J. M.","family":"Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H. M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-9924","authenticated-orcid":false,"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2008_CR1","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1371\/journal.pmed.0040209","volume":"4","author":"JJ Swen","year":"2007","unstructured":"Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209.","journal-title":"PLoS Med"},{"key":"2008_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","volume":"11","author":"R van Westrhenen","year":"2020","unstructured":"van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Juki\u0107 MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020;11:94.","journal-title":"Front Psychiatry"},{"key":"2008_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/ph17020151","volume":"17","author":"TAD Pelgrim","year":"2024","unstructured":"Pelgrim TAD, Philipsen A, Young AH, Juruena M, Jimenez E, Vieta E, et al. A new intervention for implementation of pharmacogenetics in psychiatry: a description of the PSY-PGx clinical study. Pharmaceuticals. 2024;17:151.","journal-title":"Pharmaceuticals"},{"key":"2008_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.725565","volume":"12","author":"R van Westrhenen","year":"2021","unstructured":"van Westrhenen R, Ingelman-Sundberg M. Editorial: from trial and error to individualised pharmacogenomics-based pharmacotherapy in psychiatry. Front Pharm. 2021;12:725565.","journal-title":"Front Pharm"},{"key":"2008_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.640032","volume":"12","author":"R van Westrhenen","year":"2021","unstructured":"van Westrhenen R, van Schaik RHN, van Gelder T, Birkenhager TK, Bakker PR, Houwink EJF, et al. Policy and practice review: a first guideline on the use of pharmacogenetics in clinical psychiatric practice. Front Pharmacol. 2021;12:640032.","journal-title":"Front Pharmacol"},{"key":"2008_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","volume":"83","author":"JJ Swen","year":"2008","unstructured":"Swen JJ, Wilting I, de, Goede AL, Grandia L, Mulder H, et al. Pharmacogenetics: from bench to byte. Clin Pharm Ther. 2008;83:781\u20137.","journal-title":"Clin Pharm Ther"},{"key":"2008_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 2011;89:662\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"2008_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cpt.1049","volume":"103","author":"JJ Swen","year":"2018","unstructured":"Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Pharmacogenetic information in clinical guidelines: the European perspective. Clin Pharmacol Ther. 2018;103:795\u2013801.","journal-title":"Clin Pharmacol Ther"},{"key":"2008_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41431-018-0205-4","volume":"26","author":"HJ Guchelaar","year":"2018","unstructured":"Guchelaar HJ. Pharmacogenomics, a novel section in the European Journal of Human Genetics. Eur J Hum Genet. 2018;26:1399\u2013400.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","volume":"30","author":"J Brouwer","year":"2022","unstructured":"Brouwer J, Nijenhuis M, Soree B, Guchelaar HJ, Swen JJ, van Schaik RHN, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur J Hum Genet. 2022;30:1114\u201320.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41431-023-01347-3","volume":"32","author":"L Beunk","year":"2024","unstructured":"Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk A-M, Guchelaar HJ, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet. 2024;32:278\u201385.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41431-024-01648-1","volume":"32","author":"L Beunk","year":"2024","unstructured":"Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk A-M, Guchelaar H-J, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction between CYP2D6, CYP2C19 and non-SSRI\/non-TCA antidepressants. Eur J Hum Genet. 2024;32:1371\u20137.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41431-022-01243-2","volume":"31","author":"EC Hulshof","year":"2023","unstructured":"Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet. 2023;31:982\u20137.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41431-024-01572-4","volume":"32","author":"LEN Manson","year":"2024","unstructured":"Manson LEN, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. Eur J Hum Genet. 2024;32:903\u201311.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"C Lunenburg","year":"2020","unstructured":"Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28:508\u201317.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41431-022-01262-z","volume":"31","author":"M Nijenhuis","year":"2023","unstructured":"Nijenhuis M, Soree B, Jama WOM, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate. Eur J Hum Genet. 2023;31:1364\u201370.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41431-021-00920-y","volume":"30","author":"M Matic","year":"2022","unstructured":"Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2022;30:1105\u201313.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41431-022-01180-0","volume":"32","author":"KH van der Pol","year":"2024","unstructured":"van der Pol KH, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, et al. Dutch pharmacogenetics working group guideline for the gene\u2013drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate. Eur J Hum Genet. 2024;32:155\u201362.","journal-title":"Eur J Hum Genet"},{"key":"2008_CR19","first-page":"1245","volume":"159","author":"E Trindade","year":"1998","unstructured":"Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998;159:1245\u201352.","journal-title":"CMAJ"},{"key":"2008_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241243297","volume":"14","author":"D Taylor","year":"2024","unstructured":"Taylor D, Poulou S, Clark I. The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use. Ther Adv Psychopharmacol. 2024;14:20451253241243297.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2008_CR21","unstructured":"Dutch TDM guideline for amitriptyline and nortriptyline 2022. Available from: https:\/\/tdm-monografie.org\/tca-tricyclische-antidepressiva\/."},{"key":"2008_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00007691-200304000-00018","volume":"25","author":"EJ Franssen","year":"2003","unstructured":"Franssen EJ, Kunst PW, Bet PM, Strack van Schijndel RJ, van Loenen AC, Wilhelm AJ. Toxicokinetics of nortriptyline and amitriptyline: two case reports. Ther Drug Monit. 2003;25:248\u201351.","journal-title":"Ther Drug Monit"},{"key":"2008_CR23","first-page":"1","volume":"6","author":"BG Pollock","year":"1992","unstructured":"Pollock BG, Everett G, Perel JM. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology. 1992;6:1\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"2008_CR24","unstructured":"Micromedex, nortriptyline. Available from: www.micromedexsolutions.com. [Accessed September 2014.]."},{"key":"2008_CR25","first-page":"273","volume":"30","author":"NE Hardy","year":"2021","unstructured":"Hardy NE, Walkup JT. Clomipramine in combination with fluvoxamine: a potent medication combination for severe or refractory pediatric OCD. J Can Acad Child Adolesc Psychiatry. 2021;30:273\u20137.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"2008_CR26","first-page":"150","volume":"30","author":"R Fung","year":"2021","unstructured":"Fung R, Elbe D, Stewart SE. Retrospective review of fluvoxamine-clomipramine combination therapy in obsessive-compulsive disorder in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2021;30:150\u20135.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"2008_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","volume":"21","author":"K Karamperis","year":"2021","unstructured":"Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533\u201341.","journal-title":"Pharmacogenomics J"},{"key":"2008_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2019.00830","volume":"10","author":"S Simeonidis","year":"2019","unstructured":"Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of economic evaluation to assess the feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front Pharmacol. 2019;10:830.","journal-title":"Front Pharmacol"},{"key":"2008_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"C Lunenburg","year":"2016","unstructured":"Lunenburg C, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40\u20138.","journal-title":"Eur J Cancer"},{"key":"2008_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M\u00fcller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"2008_CR31","unstructured":"CPIC. CPIC\u00ae Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19, 2019 Update. https:\/\/cpicpgx.org\/guidelines\/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19\/."},{"key":"2008_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.762","volume":"103","author":"PCD Bank","year":"2018","unstructured":"Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 2018;103:599\u2013618.","journal-title":"Clin Pharmacol Ther"},{"key":"2008_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","volume":"11","author":"H Abdullah-Koolmees","year":"2020","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol. 2020;11:595219.","journal-title":"Front Pharmacol"},{"key":"2008_CR34","unstructured":"Royal Dutch Pharmacists Association (KNMP): Pharmacogenetic Recommendation Text. https:\/\/www.knmp.nl\/ [Accessed February 2025]."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-02008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-02008-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-02008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:57:07Z","timestamp":1772715427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-02008-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-02008-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}